News

Novo Nordisk Says FDA Accepted New Drug Application for Wegovy Pill
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
Fierce Pharma12h
Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth
As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...
The Cardiology Advisor9h
Novo Nordisk Partners With Telehealth Platforms to Expand Wegovy Access
Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic ...
Healthy Returns: Novo Nordisk's Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
Eli Lilly won’t lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.
NJBIZ1d
Novo Nordisk seeks FDA approval for Wegovy weight loss pill
Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...
Top Analyst Reports for Novo Nordisk, Honeywell & American Tower
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Honeywell ...
Novo Nordisk shares pop as drugmaker sees copycat Wegovy sales easing in 2025
Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast ...
Novo Nordisk Guidance in Focus Amid Stagnant Prescription Trends -- Earnings Preview
--The company currently guides for 16%-24% sales growth at constant exchange rates and for 19%-27% operating profit growth. "With the continued weak trends in the U.S. continuing into 2Q, we now ...